Chevrolet Aveo

Made in Australia? The electric vehicle revolution gives us a chance to revive an industry

Retrieved on: 
Tuesday, April 18, 2023

As industry journal Automotive News put it:

Key Points: 
  • As industry journal Automotive News put it:
    The electric vehicle revolution isn’t coming – it’s already here.
  • US moves to adopt strict new vehicle emissions standards could drive up electric vehicle sales tenfold.
  • There are bound to be flow-on effects in Australia, where the government is about to release a national electric vehicle strategy and new vehicle emission standards.

But what’s left of vehicle manufacturing?

    • “All the bones are there,” said a former site operations manager at Holden’s Elizabeth plant in 2021.
    • They have plans for a mixed-use future with some industry – but no specific plans for a return to making cars.
    • The fragmented market issue could be overcome if the industry had an export focus, particularly for valuable vehicle parts.
    • As for labour costs, plenty of electric vehicles – or their parts – are being made in other high-wage markets.

So what’s happening in the US?

    • Many electric vehicles are made in factories that once made conventional vehicles, reviving parts of America’s “Rustbelt” in the process.
    • While Elon Musk proclaims Tesla’s flagship plant in Fremont, California, to be the “factory of the future”, it is actually a former General Motors plant.
    • In 2010, when Tesla took over the facility, it rehired many former workers.
    • Since Tesla began production in June 2012, the same buildings have been used for a highly productive assembly line.
    • “Everything is run down the same line, AV, EV, Sonic,” explained team leader Quentin Perea.
    • There was a famous strike against increased line speeds in 1972, and the factory faced closure on several occasions.

Australia must act decisively

    • Another recent Carmichael Centre report concluded Australia needs a “concerted, systematic industrial policy for EV manufacturing” to take advantage of the “enormous” and “exciting” opportunities.
    • Australia has crucial advantages, especially as vehicle makers place high value on the availability of a workforce with industry experience.

Nordstrom Appoints Atticus Tysen to Board of Directors

Retrieved on: 
Thursday, January 5, 2023

SEATTLE, Jan. 5, 2023 /PRNewswire/ -- Nordstrom, Inc. (NYSE: JWN) today announced the appointment of Atticus Tysen to its Board of Directors, effective January 3, 2023.

Key Points: 
  • SEATTLE, Jan. 5, 2023 /PRNewswire/ -- Nordstrom, Inc. (NYSE: JWN) today announced the appointment of Atticus Tysen to its Board of Directors, effective January 3, 2023.
  • Tysen has more than three decades of engineering and information security experience.
  • "Atticus is a proven leader with decades of experience in the technology and cybersecurity space," said Brad Tilden, chairman of the Nordstrom Board.
  • "His background will add to the diversity of experience already represented across our Board and help us hone an increasingly important area of focus for the retail industry.

AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

Retrieved on: 
Thursday, July 29, 2021

AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021.
  • AVEOs management team will host a conference call and audio webcast at 4:30 p.m.
  • ET on Thursday, August 5, 2021, to discuss the financial results and provide a business update.
  • AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer.

AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 10, 2021

Additional data from the TIVO-3 study will be featured during two poster presentations at the 2021 American Society of Clinical Oncology(ASCO) Annual Meeting in June 2021.

Key Points: 
  • Additional data from the TIVO-3 study will be featured during two poster presentations at the 2021 American Society of Clinical Oncology(ASCO) Annual Meeting in June 2021.
  • AVEO will serve as the study sponsor and will be responsible for costs associated with the trial execution.
  • In February 2021, AVEO presented key subgroup and quality of life analyses from the Phase 3 TIVO-3 study at the ASCO 2021 Genitourinary (GU) Cancers Symposium.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

Retrieved on: 
Friday, March 26, 2021

AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an additional 900,000 shares, at a price to the public of $8.00 per share.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an additional 900,000 shares, at a price to the public of $8.00 per share.
  • The aggregate gross proceeds to AVEO from the offering were $55.2 million, before deducting underwriting discounts and commissions and offering expenses payable by AVEO.
  • H.C. Wainwright & Co. and JonesTrading acted as co-managers for the offering.
  • These forward-looking statements include, among others, statements relating to the intended use of proceeds from the public offering.

AVEO Announces Proposed Public Offering of Common Stock

Retrieved on: 
Monday, March 22, 2021

AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.
  • In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.
  • These forward-looking statements include, among others, statements relating to AVEOs plans to consummate its proposed public offering and the intended use of proceeds therefrom.
  • There can be no assurance that AVEO will be able to complete the proposed public offering on the anticipated terms, or at all.

AVEO Oncology to Regain Ex-North American Rights to AV-203

Retrieved on: 
Monday, March 15, 2021

AVEO will regain rights to AV-203 in all territories outside of North America, and CANbridge has initiated the process to transfer all preclinical data and materials to AVEO.

Key Points: 
  • AVEO will regain rights to AV-203 in all territories outside of North America, and CANbridge has initiated the process to transfer all preclinical data and materials to AVEO.
  • To date, AVEO has completed a Phase 1, open-label, dose-escalation study of AV-203 in patients with advanced solid tumors (N=22).
  • By reacquiring rights to AV-203 outside of North America, we add global rights to a third IgG1 antibody clinical candidate within our internally developed and diverse portfolio of oncology therapeutics, said Michael Bailey, president and chief executive officer of AVEO.
  • Under their 2016 agreement, AVEO granted CANbridge Life Sciences worldwide rights, excluding the United States, Canada, and Mexico, to AV-203.

AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility

Retrieved on: 
Thursday, March 11, 2021

AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, Hercules) and its affiliates.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, Hercules) and its affiliates.
  • This second tranche was made available in connection with the recent U.S. Food and Drug Administration (FDA) approval of FOTIVDA (tivozanib).
  • With the closing of the second tranche, AVEO has drawn down a total of $35 million under its loan and security agreement with Hercules.
  • An additional $5 million tranche becomes available if net product revenues of FOTIVDA reach $20 million within a specified time frame, and the final $5 million tranche would be available after that time upon the lenders consent.

AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer

Retrieved on: 
Wednesday, March 10, 2021

AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer.

Key Points: 
  • AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer.
  • Mr. Ferraresso will be responsible for managing AVEOs commercial strategy and operations, including the commercialization of FOTIVDA (tivozanib).
  • Directly on the heels of FOTIVDAs approval, it is a pleasure to announce Mikes appointment to chief commercial officer, said Michael Bailey, president and chief executive officer of AVEO.
  • Mr. Ferraresso, who joined AVEO in December 2017, most recently served as senior vice president, business analytics and commercial operations.

AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Tuesday, March 2, 2021

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.
  • AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
  • AVEOs earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb).
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.